Gastroenterology Deal Benchmarks
IBD, Crohn's, celiac, NASH, and GI disease deal benchmarks. Benchmarks derived from 66 verified transactions.
66
Total Deals
$2.1B
Avg Upfront
3
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
26
license
26
acquisition
14
collaboration
0
option
0
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Prometheus Biosciences → Merck tulisokibart (MK-7240) | acquisition | $11.0B | $11.0B | Apr 2026 |
Telavant → Roche RVT-3101 (RO7790121) | acquisition | $7.0B | $7.0B | Apr 2026 |
Quotient Therapeutics → Merck & Co. | collaboration | $20M | $2.2B | Mar 2026 |
GSK → Alfasigma linerixibat | license | $300M | $690M | Mar 2026 |
Earendil → Sanofi AI platform and pipeline expansion (including HXN-1001) | collaboration | $160M | $2.6B | Jun 2025 |
Ribo Life Science → Madrigal Pharmaceuticals siRNA MASH portfolio | license | $60M | $4.4B | Jan 2025 |
Calypso Biotech → Novartis celiac_disease | acquisition | $250M | $425M | Jan 2025 |
Phathom Pharmaceuticals → Alfasigma gerd | acquisition | $450M | $450M | Dec 2024 |
Ventyx Biosciences → Eli Lilly crohns | acquisition | $1.2B | $1.2B | Dec 2024 |
Teva Pharmaceutical → Sanofi ulcerativeColitis | license | $500M | $2.0B | Dec 2024 |
Benchmark Your Gastroenterology Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 66 verified gastroenterology transactions.
Run Gastroenterology Benchmark